These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 34740742)

  • 1. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2021 Dec; 182():109123. PubMed ID: 34740742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Effectiveness of Quadruple Combination Therapy with Empagliflozin Versus Basal Long-Acting Insulin Therapy in Patients with Type 2 Diabetes: 3-Year Retrospective Observational Study.
    Ku EJ; Oh TK
    Diabetes Ther; 2023 Sep; 14(9):1471-1479. PubMed ID: 37369826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison Of Efficacy And Safety Profile Of Empagliflozin Versus Dapagliflozin As Add On Therapy In Type 2 Diabetic Patients.
    Hussain M; Atif M; Babar M; Akhtar L
    J Ayub Med Coll Abbottabad; 2021; 33(4):593-597. PubMed ID: 35124914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes.
    Yang AY; Chen HC
    J Diabetes Res; 2022; 2022():2420857. PubMed ID: 35656359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
    Nauck MA; Del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
    Diabetes Care; 2011 Sep; 34(9):2015-22. PubMed ID: 21816980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Obes Metab; 2019 Jan; 21(1):173-177. PubMed ID: 30039538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus.
    Kim JH; Yoon YC; Kim YH; Park JI; Choi KU; Nam JH; Lee CH; Son JW; Park JS; Kim U
    Clin Cardiol; 2024 Feb; 47(3):e24248. PubMed ID: 38436204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
    Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK.
    Evans M; Achha S; Neslusan C
    Diabetes Ther; 2017 Oct; 8(5):1175-1185. PubMed ID: 28948541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.
    Bailey CJ; Del Prato S; Wei C; Reyner D; Saraiva G
    Diabetes Obes Metab; 2019 Nov; 21(11):2564-2569. PubMed ID: 31364269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin.
    Yang AY; Chen HC
    Int J Clin Pharm; 2021 Aug; 43(4):1015-1023. PubMed ID: 33258006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin: a review of its use in type 2 diabetes mellitus.
    Plosker GL
    Drugs; 2012 Dec; 72(17):2289-312. PubMed ID: 23170914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
    Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
    Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.